Equity Securities Without Readily Determinable Fair Value - Cumulative Upward Adjustments
Merck & Co. Equity Securities Without Readily Determinable Fair Value - Cumulative Upward Adjustments increased by 9.6% to $320.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.6%, from $309.00M to $320.00M. Over 5 years (FY 2020 to FY 2025), Equity Securities Without Readily Determinable Fair Value - Cumulative Upward Adjustments shows an upward trend with a 11.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates that the company's private investment portfolio is appreciating in value based on market signals.
Detailed definition
This reflects the cumulative positive adjustments to the carrying value of equity investments that lack a readily determ...
Peer comparison
Specific to companies with venture capital or strategic investment arms.
equity_securities_no_fv_upward_adjHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $244.00M | $229.00M | $234.00M | $248.00M | $254.00M | $255.00M | $289.00M | $287.00M | $287.00M | $296.00M | $299.00M | $297.00M | $355.00M | $302.00M | $309.00M | $309.00M | $307.00M | $293.00M | $292.00M | $320.00M |
| QoQ Change | — | -6.1% | +2.2% | +6.0% | +2.4% | +0.4% | +13.3% | -0.7% | +0.0% | +3.1% | +1.0% | -0.7% | +19.5% | -14.9% | +2.3% | +0.0% | -0.6% | -4.6% | -0.3% | +9.6% |
| YoY Change | — | — | — | — | +4.1% | +11.4% | +23.5% | +15.7% | +13.0% | +16.1% | +3.5% | +3.5% | +23.7% | +2.0% | +3.3% | +4.0% | -13.5% | -3.0% | -5.5% | +3.6% |
Equity Securities Without Readily Determinable Fair Value - Cumulative Upward Adjustments at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s equity securities without readily determinable fair value - cumulative upward adjustments?
- Merck & Co. (MRK) reported equity securities without readily determinable fair value - cumulative upward adjustments of $320.00M in Q1 2026.
- How has Merck & Co.'s equity securities without readily determinable fair value - cumulative upward adjustments changed year-over-year?
- Merck & Co.'s equity securities without readily determinable fair value - cumulative upward adjustments increased by 3.6% year-over-year, from $309.00M to $320.00M.
- What is the long-term trend for Merck & Co.'s equity securities without readily determinable fair value - cumulative upward adjustments?
- Over 5 years (2020 to 2025), Merck & Co.'s equity securities without readily determinable fair value - cumulative upward adjustments has grown at a 11.6% compound annual growth rate (CAGR), from $169.00M to $292.00M.
- What does equity securities without readily determinable fair value - cumulative upward adjustments mean?
- The total amount of value increases recognized on private equity investments.